Skip to main content
SpringerLink
Log in

Clinical Outcome Measures for Multiple Sclerosis

  • Chapter
Multiple Sclerosis

Abstract

The first rating scales designed to quantitate disability due to multiple sclerosis (MS) were developed to characterize the natural history of the disease. McAlpine’s scale (McAlpine and Compston 1952) is an example, but similar scales have been devised by others. These instruments were ordinal scales oriented to mobility and had a few large steps. They could reasonably categorize patients over the broad range of disabilities encountered in MS and were satisfactory to describe the evolution of MS over decades in retrospective or cross-sectional surveys. Alexander (1951) developed a rating scale based on a weighted scoring of the formal neurologic examination, including deep tendon reflexes and Babinski signs. Mobility was one of a number of factors weighted into the composite score. These rating scales illustrate the dichotomy between rating neurologic impairment, emphasizing mobility and scoring the formal neurologic examination, including reflexes and other elements not directly linked to impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alexander L (1951) New concept of critical steps in course of chronic debilitating neurologic disease in evaluation of therapeutic response. Arch Neurol Psychiatry 66: 253–271

    CAS  Google Scholar 

  • Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L (1988) Interrater reliability in assessing functional systems and disability on the Kurtzke Scale in multiple sclerosis. Arch Neurol 45: 746–748

    PubMed  CAS  Google Scholar 

  • Arnold DL, Matthews PM, Francis G, O’Connor J, Antel JP (1992) Proton magnetic resonance spectroscopy for metabolic characterization of demyelinating plaques. Ann Neurol 31: 235–241

    Article  PubMed  CAS  Google Scholar 

  • Cohen RA, Kessler HR, Fischer M (1993) The extended disability status scale ( EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis. J Neurol Sci 115: 132–135

    Article  PubMed  CAS  Google Scholar 

  • Cook SD, Troiano R, Zito G et al. (1986) Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet i:1405–1409

    Article  Google Scholar 

  • Derogatis LR, Melisaratos N (1983) The brief symptom inventory: an introductory report. Psychol Med 13: 595–605

    Article  PubMed  CAS  Google Scholar 

  • Ellison GW, Myers LW, Leake BD et al. (1994) Design strategies in multiple sclerosis clinical trials. Ann Neurol 36: S108 - S112

    Article  PubMed  Google Scholar 

  • Filippi M, Martinelli V, Sirabian G et al. (1993) Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. J Neurol Sci 115 (Suppl): S66 - S73

    PubMed  Google Scholar 

  • Francis DA, Bain P, Swan AV, Hughes RAC (1991) An assessment of disability rating scales used in multiple sclerosis. Arch Neurol 48:299–301

    PubMed  CAS  Google Scholar 

  • Goodkin DE, Hertsgaard D, Seminary J (1988) Upper extremity function in multiple sclerosis: improving assessment sensitivity with Box-and-Block and Nine-Hole Peg tests. Arch Phys Med Rehabil 69: 850–854

    PubMed  CAS  Google Scholar 

  • Goodkin DE, Bailly RC, Teetzen NL, Hertsgaard D, Beatty WW (1991) The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 41: 20–25

    PubMed  CAS  Google Scholar 

  • Goodkin DE, Cookfair D, Wende K et al. (1992) Inter-and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale ( EDSS ). Neurology 42: 859–863

    PubMed  CAS  Google Scholar 

  • Goodkin DE, Rudick RA, Medendorp SV et al. (1995) Low dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 37: 30–40

    Article  PubMed  CAS  Google Scholar 

  • Granger CV, Cotter AC, Hamilton BB, Fiedler RC, Hens MM (1990) Functional assessment scales: a study of persons with multiple sclerosis. Arch Phys Med Rehabil 71: 870–874

    PubMed  CAS  Google Scholar 

  • Hauser SL, Dawson DM, Lehrich JR et al. (1983) Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308: 173–180

    Article  PubMed  CAS  Google Scholar 

  • IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: 1. Clinical results of a multicenter randomized, double-blind placebo-controlled trial. Neurology 43: 655–661

    Google Scholar 

  • International Federation of Multiple Sclerosis Societies (1985) Minimal Record of Disability for multiple sclerosis. National Multiple Sclerosis Society, New York

    Google Scholar 

  • Keith RA, Granger CV, Hamilton BB, Sherwin FS (1987) The functional independence measure: a new tool for rehabilitation. In: Eisenberg MG, Grzesiak RC (eds) Advances in clinical rehabilitation, vol. 1. Springer-Verlag, New York, pp 6–18

    Google Scholar 

  • Krupp LB, Alvarez LA, LaRocca NG et al. (1988) Fatigue in multiple sclerosis. Arch Neurol 45: 435–437

    PubMed  CAS  Google Scholar 

  • Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46: 1121–1123

    PubMed  CAS  Google Scholar 

  • Kurtzke JF (1955) A new scale for evaluating disability in multiple sclerosis. Neurology 5: 580–583

    PubMed  CAS  Google Scholar 

  • Kurtzke JF (1961) On the evaluation of disability in multiple sclerosis. Neurology 11: 686–694

    PubMed  CAS  Google Scholar 

  • Kurtzke JF (1965) Further notes on disability evaluation in multiple sclerosis, with scale modifications. Neurology 15: 654–661

    PubMed  CAS  Google Scholar 

  • Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444–1452

    PubMed  CAS  Google Scholar 

  • Kurtzke JF (1989a) The disability status scale for multiple sclerosis: apologia pro DSS sua. Neurology 39: 291–302

    PubMed  CAS  Google Scholar 

  • Kurtzke JF (1989b) Patterns of neurologic involvement in multiple sclerosis. Neurology 39: 1235–1238

    PubMed  CAS  Google Scholar 

  • Kurtzke JF, Beebe GW, Nagler B et al. (1977) Studies on the natural history of multiple sclerosis: VIII. Early prognostic features of the later course of the illness. J Chronic Dis 30: 819–830

    Article  PubMed  CAS  Google Scholar 

  • McAlpine D, Compston N (1952) Some aspects of the natural history of disseminated sclerosis. Q J Med 21: 135–167

    PubMed  CAS  Google Scholar 

  • Mumford CJ, Compston A (1993) Problems with rating scales for multiple sclerosis: a novel approach–the CAMBS score. J Neurol 240: 209–215

    Article  PubMed  CAS  Google Scholar 

  • Myers LS, Ellison GW, Leake BD (1993) Reliability of the disability status scale (DSS). Neurology 43 (Suppl 2): A204

    Google Scholar 

  • Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC and the Canadian Cooperative Multiple Sclerosis Study Group (1990) Interrater variability with the expanded disability status scale (EDSS) and functional systems ( FS) in a multiple sclerosis clinical trial. Neurology 40: 971–975

    Google Scholar 

  • Noseworthy JH, Rodriguez M, Weinshenker BG et al. (1994) The assessment of muscle strength in an MS clinical trial. 10th Congress of European Committee for Treatment and Research in MS (ECTRIMS). Athens, Greece, November

    Google Scholar 

  • Rao SM, Leo GJ, Naughton VM et al. (1989) Correlation of magnetic resonance in aging with neuropsychological testing. Neurology 39: 161–166

    PubMed  CAS  Google Scholar 

  • Runmarker B, Andersson C, Oden A et al. (1994) Multivariate analysis of prognostic factors in multiple sclerosis. J Neurol 241: 597–604

    Article  PubMed  CAS  Google Scholar 

  • Sipe JC, Knobler RL, Braheny SL, Rice GPA, Panitch HS, Oldstone MBA (1984) A neurologic rating scale ( NRS) for use in multiple sclerosis. Neurology 34: 1368–1372

    PubMed  CAS  Google Scholar 

  • Syndulko K, Tourtellotte WW, Baumhefner RW et al. (1993) Neuroperformance evaluation of multiple sclerosis disease progression in a clinical trial: implications for neurological outcomes. J Neurol Rehabil 7: 153–176

    Google Scholar 

  • Tourtellotte WW, Haerer AF, Simpson JF, Kuzma JW, Sikorski J (1965) Quantitative clinical neurological testing: I. A study of a battery of tests designed to evaluate in part the neurologic function of patients with multiple sclerosis and its use in a therapeutic trial. Ann NY Acad Sci USA 122: 480–505

    Article  CAS  Google Scholar 

  • Verdier-Taillefer MH, Zuber M, Lyon-Caen O et al. (1991) Observer disagreement in rating neurologic impairment in multiple sclerosis: Facts and consequences. Eur Neurol 31: 117–119

    Article  PubMed  CAS  Google Scholar 

  • Weinshenker BG (1995) The natural history of multiple sclerosis. Neurol Clin 13: 119–146

    PubMed  CAS  Google Scholar 

  • Weinshenker BG, Gass B, Rice GPA et al. (1989) The natural history of multiple sclerosis: a geographically based study: 2. Predictive value of the early clinical course. Brain 112: 1419–1428

    Article  PubMed  Google Scholar 

  • Weinshenker BG, Rice GPA, Noseworthy JH et al. (1991) The natural history of multiple sclerosis: a geographically based study: 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114: 1057–1067

    Article  PubMed  Google Scholar 

  • Weinshenker BG, Issa M, Baskerville J (in press) Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology

    Google Scholar 

  • Wiebe S, Lee DH, Karlik SJ et al. (1992) Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis: clinical correlations and implications for classification of disease course. Ann Neurol 32: 643–650

    Article  PubMed  CAS  Google Scholar 

  • Willoughby EW, Paty DW (1988) Scales for rating impairment in multiple sclerosis: A critique. Neurology 38: 1793–1798

    Google Scholar 

Download references

Authors
  1. Brian G. Weinshenker
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The UCSF/Mount Zion Multiple Sclerosis Center, University of California at San Francisco, 1600 Divisadero Street, 94115, San Francisco, CA, USA

    Donald E. Goodkin MD

  2. Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195-5244, Cleveland, OH, USA

    Richard A. Rudick MD

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag London Limited

About this chapter

Cite this chapter

Weinshenker, B.G. (1996). Clinical Outcome Measures for Multiple Sclerosis. In: Goodkin, D.E., Rudick, R.A. (eds) Multiple Sclerosis. Springer, London. https://doi.org/10.1007/978-1-4471-1271-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-1271-6_5

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-033-0

  • Online ISBN: 978-1-4471-1271-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation